IL160097A0 - Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof - Google Patents
Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereofInfo
- Publication number
- IL160097A0 IL160097A0 IL16009702A IL16009702A IL160097A0 IL 160097 A0 IL160097 A0 IL 160097A0 IL 16009702 A IL16009702 A IL 16009702A IL 16009702 A IL16009702 A IL 16009702A IL 160097 A0 IL160097 A0 IL 160097A0
- Authority
- IL
- Israel
- Prior art keywords
- ylidene
- carboxamide
- diethylamino
- indole
- pyrrole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31235301P | 2001-08-15 | 2001-08-15 | |
PCT/US2002/025649 WO2003016305A1 (fr) | 2001-08-15 | 2002-08-13 | Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160097A0 true IL160097A0 (en) | 2004-06-20 |
Family
ID=23211067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16009702A IL160097A0 (en) | 2001-08-15 | 2002-08-13 | Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
Country Status (43)
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016305A1 (fr) | 2001-08-15 | 2003-02-27 | Pharmacia & Upjohn Company | Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes |
TW200418836A (en) * | 2002-09-10 | 2004-10-01 | Pharmacia Italia Spa | Formulations comprising an indolinone compound |
PT1670785E (pt) * | 2003-10-02 | 2010-09-16 | Pharmacia & Upjohn Co Llc | Sais e polimorfos de um composto de indolinona substituída com pirrole |
US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
MX2007000892A (es) * | 2004-07-22 | 2007-05-23 | Lilly Co Eli | Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato. |
WO2006120557A1 (fr) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Polytherapie anticancereuse faisant intervenir du malate de sunitinib |
CN101287724B (zh) | 2005-09-19 | 2013-11-06 | 硕腾P有限责任公司 | 经吡咯取代的2-吲哚酮的固态盐形式 |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
CA2699305A1 (fr) * | 2007-11-21 | 2009-05-28 | Teva Pharmaceutical Industries Ltd. | Polymorphes de base de sunitinib et procedes pour les preparer |
CN101939314B (zh) * | 2007-12-12 | 2014-04-02 | 麦迪凯姆股份公司 | 3-吡咯取代的2-吲哚酮的多晶型物 |
EP2090306A1 (fr) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
EP2113248A1 (fr) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Composition pharmaceutique comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-dimethyl-1H-pyrrole-3-carboxamide |
CN101983195A (zh) * | 2008-02-21 | 2011-03-02 | 基因里克斯(英国)有限公司 | 新型多晶型物及其制备方法 |
EP2098521A1 (fr) * | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Formules cristallines de N-[2-(diéthylamino)éthyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidène)méthyl]-2,4-diméthyl-1H-pyrrole-3-carboxamide |
WO2009124037A1 (fr) * | 2008-03-31 | 2009-10-08 | Teva Pharmaceutical Industries Ltd. | Procédés de préparation de sunitinib et de sels de ce dernier |
CA2720943A1 (fr) | 2008-04-16 | 2009-10-22 | Natco Pharma Limited | Nouvelles formes polymorphes du sunitinib base |
US8829039B2 (en) | 2008-05-23 | 2014-09-09 | Shanghai Institute Of Pharmaceutical Industry | Dihydroindolinone derivatives |
EP2313371B1 (fr) * | 2008-06-13 | 2012-08-15 | Medichem, S.A. | Procédé de préparation d un sel 2-indolinone malate à substitution 3 pyrrole |
EP2138167A1 (fr) | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
WO2009156837A2 (fr) * | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole |
US20110257237A1 (en) * | 2008-07-10 | 2011-10-20 | Generics [Uk] Limited | Process for the preparation of crystalline forms of sunitinib malate |
CN102164913A (zh) * | 2008-07-24 | 2011-08-24 | 麦迪凯姆股份公司 | 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式 |
EP2373642A2 (fr) * | 2008-07-24 | 2011-10-12 | Teva Pharmaceutical Industries Ltd | Sunitinib et ses sels et leurs polymorphes |
CN102197034A (zh) * | 2008-08-25 | 2011-09-21 | 基因里克斯(英国)有限公司 | 舒尼替尼的新型多晶型物及其制备方法 |
CA2734965A1 (fr) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Nouvelle forme cristalline et ses procedes de preparation |
EP2350056A1 (fr) * | 2008-10-10 | 2011-08-03 | Medichem, S.A. | Procédé pour la préparation d'un sel de malate de 2-indolinone substituée par pyrrole en position 3 |
EP2181991A1 (fr) | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Nouveaux sels de sunitinib |
EP2186809A1 (fr) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | Nouvelle forme cristalline du malate de sunitinib |
EP2373643A4 (fr) * | 2009-01-02 | 2013-08-07 | Hetero Research Foundation | Nouveaux polymorphes de malate de sunitinib |
WO2010083414A1 (fr) | 2009-01-16 | 2010-07-22 | Exelixis, Inc. | Sel de malate de n-(4-{[6,7-bis(méthyloxy)quinolin-4-yl]oxy}phényl)-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide et formes cristallines de celui-ci pour le traitement du cancer |
EP2255792A1 (fr) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Composition pharmaceutique pour n-[2-(diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1h-pyrrole-3-carboxamide |
WO2011004200A1 (fr) | 2009-07-10 | 2011-01-13 | Generics [Uk] Limited | Nouveaux dérivés de pyrrole |
CA2774634A1 (fr) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Sels de sunitinib |
WO2011058521A2 (fr) * | 2009-11-12 | 2011-05-19 | Ranbaxy Laboratories Limited | Procédé de préparation de la forme cristalline i du sel d'acide l-malique de sunitinib |
WO2011061613A1 (fr) | 2009-11-19 | 2011-05-26 | Ranbaxy Laboratories Limited | Procédé de préparation de la forme cristalline ii du sel d'acide malique l du sunitinib |
EP2528913A1 (fr) | 2010-01-29 | 2012-12-05 | Ranbaxy Laboratories Limited | Formes cristallines du sel d'acide l-malique du sunitinib |
WO2011100325A2 (fr) | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphes de sels de sunitinib |
WO2011104555A2 (fr) | 2010-02-25 | 2011-09-01 | Generics [Uk] Limited | Nouveau procédé |
US20130123511A1 (en) | 2010-03-04 | 2013-05-16 | Ranbaxy Laboratories Limited | Process for the direct preparation of malic acid salt of sunitinib |
US20160185760A1 (en) | 2010-03-18 | 2016-06-30 | Ranbaxy Laboratories Limited | Process for the preparation of malic acid salt of sunitinib |
WO2011128699A2 (fr) | 2010-04-16 | 2011-10-20 | Generics [Uk] Limited | Procédés inédits |
WO2012042421A1 (fr) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Procédé de traitement de la croissance cellulaire anormale |
ES2724801T3 (es) | 2011-04-19 | 2019-09-16 | Pfizer | Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer |
EP2828251B1 (fr) | 2012-03-23 | 2018-10-31 | Laurus Labs Limited | Procédé perfectionné pour la préparation de sunitinib et de ses sels d'addition avec un acide |
PL399027A1 (pl) | 2012-04-27 | 2013-10-28 | Instytut Farmaceutyczny | Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu |
SG11201406592QA (en) | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
CA2838585A1 (fr) * | 2013-10-18 | 2015-04-18 | Hari Babu Matta | Sel de sunitinib d'acide ascorbique |
CA2838587A1 (fr) * | 2013-10-18 | 2015-04-18 | Hari Babu Matta | Forme cristalline pure ii de sel d'acide l-malique de sunitinib et procede pour sa preparation |
SG11201602625YA (en) | 2013-11-01 | 2016-05-30 | Pfizer | Vectors for expression of prostate-associated antigens |
CN104693187A (zh) * | 2013-12-10 | 2015-06-10 | 安杰世纪生物科技(北京)有限公司 | 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法 |
CN104744442B (zh) * | 2013-12-25 | 2019-05-28 | 江苏豪森药业集团有限公司 | 苹果酸舒尼替尼的制备方法 |
RU2567535C1 (ru) * | 2014-10-01 | 2015-11-10 | Олег Ростиславович Михайлов | КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ |
CN105712979A (zh) * | 2014-12-05 | 2016-06-29 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种苹果酸舒尼替尼晶型ⅰ的制备方法 |
EP3539536A1 (fr) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | Composition pharmaceutique de sunitinib ou de son sel dans sa forme polymorphe i |
WO2020216450A1 (fr) | 2019-04-25 | 2020-10-29 | Synthon B.V. | Composition pharmaceutique comprenant du sunitinib amorphe |
US20220192989A1 (en) * | 2019-04-18 | 2022-06-23 | Meter Health, Inc. | Methods and compositions for treating respiratory arrhythmias |
KR20240025990A (ko) | 2022-08-19 | 2024-02-27 | 주식회사 스카이테라퓨틱스 | 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0592438T5 (da) | 1990-10-15 | 1999-12-06 | Pfizer Inc. | Indolderivater |
IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole) |
SK279211B6 (sk) | 1992-06-05 | 1998-08-05 | Merck Sharp & Dohme Limited | Sulfátová soľ substituovaného triazolu, spôsob jej |
EP0690864B1 (fr) | 1993-03-12 | 2001-06-13 | PHARMACIA & UPJOHN COMPANY | Celtiofur (acide libre) cristalline |
US6329364B1 (en) | 1994-08-31 | 2001-12-11 | Eli Lilly And Company | Crystalline form of dihydro-2,3-benzodiazepine derivative |
DE19503966C2 (de) | 1995-02-07 | 1998-07-02 | Mack Chem Pharm | Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung |
US5597663A (en) * | 1995-05-30 | 1997-01-28 | Motorola, Inc. | Low temperature molten lithium salt electrolytes for electrochemical cells |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5673451A (en) * | 1995-07-06 | 1997-10-07 | Moore; James R. | Instructional toothbrush |
US20020038021A1 (en) | 1995-12-11 | 2002-03-28 | Barton Kathleen P. | Eplerenone crystalline form exhibiting enhanced dissolution rate |
US20020045746A1 (en) | 1995-12-11 | 2002-04-18 | Barton Kathleen P. | Eplerenone crystalline form |
US6066647A (en) | 1996-07-29 | 2000-05-23 | Pfizer Inc. | Zwitterionic forms of trovafloxacin |
PL191313B1 (pl) * | 1996-08-14 | 2006-04-28 | Searle & Co | Postać krystaliczna 4-[5-metylo-3-fenyloizoksazol-4-ilo] benzenosulfonamidu, sposób jej otrzymywania, zawierająca ją kompozycja farmaceutyczna i zastosowania |
CN1104378C (zh) | 1996-12-25 | 2003-04-02 | 日本化药株式会社 | 顺铂细粉及其制备方法 |
US5777185A (en) * | 1997-09-09 | 1998-07-07 | Laroche Industries Inc. | Production of organic fluorine compounds |
US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
US6012678A (en) * | 1998-01-26 | 2000-01-11 | The Boeing Company | Galley vacuum waste disposal system |
HU229405B1 (en) * | 1998-06-19 | 2013-12-30 | Teijin Pharma Ltd | Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and processes for the preparation thereof |
WO2000035908A1 (fr) * | 1998-12-17 | 2000-06-22 | F. Hoffmann-La Roche Ag | 4-alcenyl (et alcynyl) oxindoles utilises comme inhibiteurs de kinases dependantes des cyclines, en particulier la cdk2 |
US6239141B1 (en) | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
WO2001037820A2 (fr) * | 1999-11-24 | 2001-05-31 | Sugen, Inc. | Formulations pour agents pharmaceutiques ionisables comme acides libres ou bases libres |
WO2001060814A2 (fr) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole |
US6316672B1 (en) | 2001-01-31 | 2001-11-13 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
WO2003016305A1 (fr) | 2001-08-15 | 2003-02-27 | Pharmacia & Upjohn Company | Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes |
CN101983195A (zh) | 2008-02-21 | 2011-03-02 | 基因里克斯(英国)有限公司 | 新型多晶型物及其制备方法 |
WO2009156837A2 (fr) | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole |
-
2002
- 2002-08-13 WO PCT/US2002/025649 patent/WO2003016305A1/fr active IP Right Grant
- 2002-08-13 HU HU0700036A patent/HU229206B1/hu unknown
- 2002-08-13 EA EA200400183A patent/EA006445B9/ru unknown
- 2002-08-13 PT PT2759342T patent/PT1419151E/pt unknown
- 2002-08-13 MX MXPA04001452A patent/MXPA04001452A/es active IP Right Grant
- 2002-08-13 GE GE5446A patent/GEP20063777B/en unknown
- 2002-08-13 EP EP11156767.3A patent/EP2332934B1/fr not_active Expired - Lifetime
- 2002-08-13 CN CNB02815892XA patent/CN100439360C/zh not_active Expired - Lifetime
- 2002-08-13 SI SI200231043T patent/SI1419151T1/sl unknown
- 2002-08-13 SK SK90-2004A patent/SK902004A3/sk unknown
- 2002-08-13 JP JP2003521228A patent/JP4159988B2/ja not_active Expired - Lifetime
- 2002-08-13 CN CNB2005101286242A patent/CN100364991C/zh not_active Expired - Lifetime
- 2002-08-13 AU AU2002324684A patent/AU2002324684B2/en not_active Expired
- 2002-08-13 US US10/218,985 patent/US20030069298A1/en not_active Abandoned
- 2002-08-13 TR TR2019/00509T patent/TR201900509T4/tr unknown
- 2002-08-13 EP EP02759342.5A patent/EP1419151B1/fr not_active Expired - Lifetime
- 2002-08-13 ES ES11156767.3T patent/ES2623094T3/es not_active Expired - Lifetime
- 2002-08-13 BR BR0211612-0A patent/BR0211612A/pt not_active Application Discontinuation
- 2002-08-13 ES ES02759342.5T patent/ES2453164T3/es not_active Expired - Lifetime
- 2002-08-13 OA OA1200400044A patent/OA12650A/en unknown
- 2002-08-13 KR KR1020047002173A patent/KR100639281B1/ko active IP Right Grant
- 2002-08-13 ME MEP-2008-520A patent/ME00414B/me unknown
- 2002-08-13 PL PL368317A patent/PL216524B1/pl unknown
- 2002-08-13 CA CA002455050A patent/CA2455050C/fr not_active Expired - Lifetime
- 2002-08-13 DK DK02759342.5T patent/DK1419151T3/da active
- 2002-08-13 AP APAP/P/2004/002976A patent/AP1660A/en active
- 2002-08-13 UA UA2004021084A patent/UA76483C2/uk unknown
- 2002-08-13 DK DK16196036.4T patent/DK3168218T3/en active
- 2002-08-13 EP EP16196036.4A patent/EP3168218B1/fr not_active Expired - Lifetime
- 2002-08-13 PT PT16196036T patent/PT3168218T/pt unknown
- 2002-08-13 IL IL16009702A patent/IL160097A0/xx active IP Right Grant
- 2002-08-13 ES ES16196036T patent/ES2705063T3/es not_active Expired - Lifetime
- 2002-08-13 NZ NZ531232A patent/NZ531232A/en not_active IP Right Cessation
- 2002-08-13 SI SI200231093T patent/SI3168218T1/sl unknown
- 2002-08-13 RS YU10304A patent/RS53251B/sr unknown
- 2002-08-13 CZ CZ2004196A patent/CZ2004196A3/cs unknown
- 2002-08-15 TW TW091118419A patent/TWI269796B/zh active
- 2002-08-15 MY MYPI20023032A patent/MY139383A/en unknown
- 2002-08-15 AR ARP020103088A patent/AR036261A1/es unknown
-
2004
- 2004-01-16 CO CO04002781A patent/CO5550431A2/es not_active Application Discontinuation
- 2004-01-28 ZA ZA2004/00706A patent/ZA200400706B/en unknown
- 2004-01-29 BG BG108553A patent/BG108553A/bg unknown
- 2004-02-02 HR HR20040112A patent/HRP20040112B1/xx not_active IP Right Cessation
- 2004-02-10 IS IS7147A patent/IS7147A/is unknown
- 2004-02-10 EC EC2004004975A patent/ECSP044975A/es unknown
- 2004-02-11 MA MA27522A patent/MA27058A1/fr unknown
- 2004-02-12 CU CU20040029A patent/CU23713B7/es active IP Right Grant
- 2004-02-12 TN TNP2004000028A patent/TNSN04028A1/fr unknown
- 2004-03-12 NO NO20041054A patent/NO326508B1/no not_active IP Right Cessation
- 2004-12-01 HK HK04109465.3A patent/HK1066542A1/xx not_active IP Right Cessation
-
2006
- 2006-07-28 HK HK06108404A patent/HK1088008A1/xx not_active IP Right Cessation
-
2007
- 2007-04-26 US US11/740,644 patent/US7435832B2/en not_active Expired - Lifetime
-
2018
- 2018-12-12 CY CY20181101336T patent/CY1121552T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL160097A0 (en) | Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof | |
PT1488790E (pt) | Preparação sólida contendo uma forma de cristal único a de um derivado de ácido tiazolcarboxílico | |
HK1086263A1 (en) | Crystal form of lercanidipine hydrochloride for use as an antihypertensive agent | |
WO2002010154A3 (fr) | Amides heterocycliques substitues | |
IL189358A0 (en) | Novel process for the synthesis of 5 - (4 - fluorophenyl) - 1 - [2 - ((2r, 4r)- 4 - hydroxy - 6 - oxo -tetrahydro - pyran - 2 - yl) - ethyl] - 2 - isopropyl- 4 - phenyl - 1h - pyrrole - 3 - carboxylic acid phenylamide | |
WO2006025070A3 (fr) | Nebivolol et ses sels pharmaceutiquement acceptables, procede de preparation et compositions pharmaceutiques de nebivolol | |
HUP0400236A3 (en) | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride, process for their preparation and pharmaceutical compositions containing them | |
IL141767A0 (en) | Use of heteroaryl substituted n- (indole-2-carbonyl-) amides for treatment of infection | |
IL162456A0 (en) | A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochlor | |
AP2001002330A0 (en) | Polymorph of 5-¬4¬2-(n-methyl-n-(2 pyridyl) amino) ethocy¾ benyl¾ thiazoline-2, 4-dione maleic acid salt | |
HUP0401694A3 (en) | Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use | |
AU2003223637A1 (en) | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan) | |
AU2001267886A1 (en) | Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them | |
IL161275A0 (en) | [[2-(amino-3,4-dioxo-1cyclobuten-1-yl) amino] alkyl] acid derivatives for the treatment of pain | |
PL368352A1 (en) | Process for preparation of $g(a)-hydroxycarboxylic acid amides | |
AU2003274518A8 (en) | A process for the preparation of benzyl 2-oxo-4- (heteroaryl) dithio-alpha-isoprenyl-1- azetidineazetate derivatives | |
AU2003260813A8 (en) | Improved process for preparation of thiazolidinedione derivatives | |
AU2002364804A8 (en) | Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses | |
PL372137A1 (en) | A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochloride polymorphs and amorphous form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed |